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Lymphoma’ modern understanding 
• Lymphoma is any of a group of blood cell tumors   
that develop from lymphatic cells with the enlarged 
lymph nodes and signs and symptoms that may 
include enlarged lymph nodes, fever, night  
drenching sweats, unintended weight loss, itching, 
and feeling tired 
• The two main categories of lymphomas are Hodgkin 
(HL) and the non-Hodgkin (NHL) lymphomas 
• The World Health Organization (WHO) includes two 
other categories as types of lymphoma: multiple 
myeloma and immunoproliferative diseases   
https://en.wikipedia.org/wiki/Lymphoma  
HODGKIN LYMPHOMA 
Definition 
• Hodgkin (Hodgkin's) lymphoma or Hodgkin's 
disease, is a type of the most curable forms of 
lymphoma, in which cancer originates from the 
lymphocytes 
• Hodgkin Lymphoma is named for Dr. Thomas 
Hodgkin, who first noted a trend of cancer cases in 
the lymph nodes in 1832 
• The disease was called Hodgkin's disease until it 
was officially renamed Hodgkin lymphoma in the 
late 20th century  
https://www.lls.org/lymphoma https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
Epidemiology   
Incidence of Hodgkin Lymphoma in the United 
States, by age 
http://www.cancernetwork.com/articles/hodgkin-lymphoma-older-patients-uncommon-disease-need-study  
Risk factors and etiology 1  
• Epstein-Barr virus infection/mononucleosis 
(sometimes called mono for short) 
• Age (HL is most common in early adulthood (ages 
15 to 40, especially in a person’s 20s) and in late 
adulthood (after age 55)) 
• Gender (HD occurs slightly more often in males 
than in females) 
• Geography (HD is most common in the United 
States, Canada, and northern Europe, and is least 
common in Asian countries)  
http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-risk-factors  
Risk factors and etiology 2  
• Family history (brothers and sisters of young people 
with HD have a higher risk for Hodgkin disease) 
• Socioeconomic status (the risk is greater in people 
with a higher socioeconomic background) 
• HIV infection (the risk is increased in people 
infected with HIV) 
• In most cases, the etiology of HL is unknown 
 
http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-risk-factors  
Mechanisms 1 
The derivation of Hodgkin and Reed-Sternberg cells in 
classic HL and lymphomatic and histiocytic cells in 
noduler lymphocyte-predominant HL 
http://www.medscape.com/viewarticle/559870_4  
Mechanisms 2 
A possible model of pathogenesis (RS - Reed-
Sternberg cells ) 
http://www.slideshare.net/tashagarwal/hodgkin-lymphoma-43956683  
Classification   
Four pathologic subtypes of HL based upon Reed–
Sternberg cell morphology and the composition of the 
reactive cell infiltrate seen in the lymph node biopsy 
• Nodular sclerosing 
• Mixed-cellularity subtype 
• Lymphocyte-rich 
• Lymphocyte depleted 
• Unspecified 
 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
Сlassification   
the Ann Arbor staging classification scheme 1  
http://www.lymphomation.org/stage.htm  https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
I   - is involvement of a single lymph node region (I) 
(mostly the cervical region) or single extralymphatic 
site    
Сlassification   
the Ann Arbor staging classification scheme 2  
http://www.lymphomation.org/stage.htm  https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
II  - is involvement of two or more lymph node regions 
on the same side of the diaphragm or of one lymph 
node region and a contiguous extralymphatic site  
Сlassification   
the Ann Arbor staging classification scheme 3  
http://www.lymphomation.org/stage.htm  https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
III - is involvement of lymph node regions on both 
sides of the diaphragm, which may include the spleen 
and/or limited contiguous extralymphatic organ or 
site   
Classification   
the Ann Arbor staging classification scheme 4  
http://www.lymphomation.org/stage.htm  https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
IV - is disseminated involvement of one or more 
extralymphatic organs 
Clinical presentation 1 
• The painless enlargement of one or more lymph 
nodes, or lymphadenopathy 
• Itchy skin 
• Night sweats 
• Red-coloured patches, easy bleeding 
and petechiae (low platelet count) 
• Cyclical high-grade (Pel-Ebstein or simply P-E) fever  
• Unexplained weight loss  
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Clinical presentation 2 
• Splenomegaly in about 30% of cases   
• Hepatomegaly in about 5% of cases 
• Pain following alcohol consumption    
• Lower back pain  
• Nephrotic syndrome   
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Clinical presentation 3 
Itchy 
skin 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Lump in 
Neck  
On the left side of the 
patient's neck enlarged 
lymph node 
Clinical presentation 4 
Pel-Ebstein Fever 
http://3.bp.blogspot.com/-QPLZFoWiVvs/Ufp1Y44yiqI/AAAAAAAAAxM/5RvtHq3FGlY/s1600/Pel-Ebstein.png  
 
 
Diagnosis 1 
• HL must be distinguished from non-cancerous 
causes of lymph node swelling and from other types 
of cancer 
• Definitive diagnosis is by lymph node biopsy with 
microscopic examination: 
• effacement of the lymph node architecture by 
scattered large malignant Reed-Sternberg 
cells (RSC)  admixed within a reactive cell 
infiltrate of lymphocytes, histiocytes, eosinophils, 
and plasma cells   
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Diagnosis 2 
• RSC are identified as large often bi-nucleated 
cells with prominent nucleoli and an 
unusual CD45-, CD30+, CD15+/- 
immunophenotype 
• in 50% of cases, the RSC are infected by the 
Epstein–Barr virus 
• the cell histology in HL is not as important as it is 
in non-Hodgkin's lymphoma  
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Diagnosis 3 
• Blood tests are performed to assess function of 
major organs and to assess safety for chemotherapy 
• Positron emission tomography is used to detect 
small deposits that are not shown on CT scanning 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Diagnosis 4 
Reed-Sternberg cells 
http://library.med.utah.edu/WebPath/jpeg5/HEME045.jpg https://s-media-cache-ak0.pinimg.com/736x/ac/06/20/ac0620621ea55abba1545f8bdf0711ee.jpg   
 
 
Diagnosis 5 
Reed-Sternberg cells 
https://secure.health.utas.edu.au/intranet/cds/pathprac/Files/Cases/Lymphatic/Case76/Pictures76/M2.jpg  
 
 
Diagnosis 6 
A) Flow cytometric immunophenotyping 
B) Fluorescence  in situ hybridization (FISH)    
https://www.mskcc.org/clinical-updates/diagnostic-accuracy-enhanced-genomic-profile-immunophenotyping  
 
 
Treatment 1   
• Treatment is tailored to HL type, disease stage, and 
an assessment of the risk of resistant disease  
• Patients with early stage disease are effectively 
treated with radiation therapy or chemotherapy: 
adding localised radiation therapy after the 
chemotherapy regimen controls the tumors better 
and provides a better chance for survival than 
chemotherapy alone  
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Treatment 2   
• Patients of any stage with a large mass in the chest 
are usually treated with combined chemotherapy 
and radiation therapy, and stem cell transplantation 
• Radiation oncologists typically use external beam 
radiation therapy  
• The high cure rates and long survival of many 
patients has led to a high concern with late adverse 
effects of treatment, including cardiovascular 
disease and second malignancies such as 
acute leukemias, lymphomas, and solid tumors 
within the radiation therapy field 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Prognosis 
• Treatment of HL has been improving over the past 
few decades 
• New types of chemotherapy have indicated higher 
survival rates than have previously been seen, and 
the 5-year survival rate for those patients with a 
favorable prognosis was 98%, while that for patients 
with worse outlooks was at least 85% 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
NON-HODGKIN LYMPHOMA 
Definition 
• Non-Hodgkin lymphomas (Non-Hodgkin’s 
lymphoma, Non-Hodgkin lymphomas, non-Hodgkin 
disease - NHL) are diverse group of blood 
cancers  that include any kind of lymphomas 
except HL, and  vary significantly in their severity, 
from slow growing to very aggressive types  
• NHL affects the lymphatic system, generally 
develops in the lymph nodes and lymphatic tissues, 
and in some cases, involves bone marrow and blood 
https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma https://www.lls.org/lymphoma   
Epidemiology   
Percent of New Cases by Age Group: Non-Hodgkin 
Lymphoma 
http://seer.cancer.gov/statfacts/html/nhl.html#  
Risk factors and etiology 1  
There are many types of NHL, and some of the risk 
factors and etiology  factors have been linked only to 
certain types: 
• Getting older is a strong risk factor for NHL overall, 
with most cases occurring after 60s 
• The risk is higher in men than in women, but there 
are certain types that are more common in women  
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 2  
There are many types of NHL, and some of the risk 
factors and etiology  factors have been linked only to 
certain types: 
• In the USA, whites are more likely than African 
Americans and Asian Americans to develop NHL 
• NHL is more common in developed countries 
• Some types of NHL that have been linked to specific 
infections are more common in certain parts of the 
world  
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 3 
• Some chemicals (benzene and certain herbicides 
and insecticides) and some chemotherapy drugs 
may be linked with an increased risk of NHL  
• Studies of survivors of atomic bombs and nuclear 
reactor accidents have shown they have an 
increased risk of developing several types of cancer, 
including NHL 
• Patients treated with radiation therapy for some 
other cancers, have a slightly increased risk of 
developing NHL later in life   
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 4 
• People with weakened immune system including 
people infected with HIV have an increased risk for 
NHL 
• Some genetic (inherited) syndromes can cause 
children to be born with a deficient immune system 
and a higher risk of developing NHL 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 5  
• Some autoimmune diseases (rheumatoid arthritis, 
systemic lupus erythematosus, Sjogren disease, 
gluten-sensitive enteropathy, and others) have been 
linked with an increased rate of NHL 
• Some types of infections may raise the risk of NHL 
in different ways 
• Some viruses (the human T-cell 
leukemia/lymphoma virus (HTLV-1) and the Epstein-
Barr virus (EBV) and human herpes virus 8 (HHV8)) 
can directly affect the DNA of lymphocytes, helping 
to transform them into cancer cells  
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 6 
•  Some long-term infections (Helicobacter pylori, 
Chlamydophila psittaci, Campylobacter jejuni) may 
increase a person’s risk of NHL by forcing their 
immune system to be constantly activated 
• The hepatitis C virus (HCV)  also can lead to the 
development of cancer, particularly hepatocellular 
carcinoma and non-Hodgkin lymphoma 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Risk factors and etiology 7 
• Some studies have suggested that being overweight 
or obese may increase your risk of NHL 
• Other studies have suggested that a diet high in fat 
and meats may raise NHL risk 
• Some women develop anaplastic large cell 
lymphoma in the scar tissue around their breast 
implants 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Mechanisms   
NHL does not involve Reed-Sternberg cells 
http://www.shaltech.com/about-lymphoma/  
Classification  1 
The three most commonly used classification 
schemas for NHL are as follows: 
• National Cancer Institute’s Working Formulation 
(IWF) classified and grouped NHL by morphology 
and clinical behavior (i.e., low, intermediate, or high 
grade) with 10 subgroups labeled A to J 
• Revised European-American Classification of 
Lymphoid Neoplasms (REAL) attempted to apply 
immunophenotypic and genetic features in 
identifying distinct clinicopathologic NHL entities  
 
http://emedicine.medscape.com/article/2500022-overview  
Classification  2 
The three most commonly used classification 
schemas for NHL are as follows: 
•  World Health Organization (WHO) 
classification divides NHL into two groups: those of 
B-cell origin and those of T-cell/natural killer (NK)–
cell origin 
 
http://emedicine.medscape.com/article/2500022-overview  
Classification  3 
 IWF  
• Low-grade subtypes: A. Small lymphocytic; B. 
Follicular, predominantly small-cleaved cell; C. 
Follicular, mixed small-cleaved, and large cell 
• Intermediate-grade subtypes: D. Follicular, 
predominantly large cell; E. Diffuse, small-cleaved 
cell; F. Diffuse mixed, small and large cell; G. Diffuse, 
large cell, cleaved, or noncleaved cell 
• High-grade subtypes: H. Immunoblastic, large cell; I. 
Lymphoblastic, convoluted, or nonconvoluted cell; J. 
Small noncleaved-cell, Burkitt, or non-Burkitt 
 
http://emedicine.medscape.com/article/2500022-overview  
Classification  4 
REAL  
• The classification is comprehensive, including HL 
and NHL, as well as the lymphoid leukemias 
• Three major categories of lymphoid neoplasia were 
agreed upon: B-cell, T/natural killer (NK)-cell, and 
Hodgkin's disease 
• The consensus panel recognized "definite," 
"provisional," and "unclassifiable" subsets 
• The classification is intended to be a flexible 
framework, subject to modification   
http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
Classification  5 
WHO 
B-cell neoplasms: chronic lymphocytic leukemia/small 
lymphocytic lymphoma, prolymphocytic leukemia, 
lymphoplasmacytic lymphoma/immunocytoma, 
Mantle cell lymphoma, follicular lymphoma, 
extranodal marginal zone B-cell lymphoma of mucosa-
associated lymphatic tissue (MALT) type, nodal 
marginal zone B-cell lymphoma (± monocytoid B 
cells), splenic marginal zone lymphoma (± villous 
lymphocytes), hairy cell leukemia, plasmacytoma/ 
plasma cell myeloma, diffuse large B-cell lymphoma 
(DLBCL), Burkitt lymphoma  http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
Classification  5 
 WHO  
Peripheral T-cell and NK-cell neoplasms: T-cell chronic 
lymphocytic leukemia/prolymphocytic leukemia, T-cell 
granular lymphocytic leukemia, mycosis fungoides/ 
Sézary syndrome, peripheral T-cell lymphoma not 
otherwise characterized, hepatosplenic gamma/delta 
T-cell lymphoma, subcutaneous panniculitis-like T-cell 
lymphoma, angioimmunoblastic T-cell lymphoma, 
extranodal T-/NK-cell lymphoma, nasal type, 
enteropathy-type intestinal T-cell lymphoma, adult T-
cell lymphoma/leukemia (human T-lymphotrophic 
virus [HTLV] 1+), etc. http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
Clinical presentation 1 
• The clinical presentation of NHL varies 
tremendously depending upon the their type and 
the areas of involvement 
• Some NHLs behave indolently with 
lymphadenopathy waxing and waning over years, 
and others are highly aggressive, resulting in death 
within weeks if left untreated 
• Indolent NHL are often insidious, presenting only 
with slow growing lymphadenopathy, 
hepatomegaly, splenomegaly, or cytopenias   
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma  
 
 
Clinical presentation 2 
• Aggressive NHL commonly present acutely or 
subacutely with a rapidly growing mass, systemic B 
symptoms (i.e., fever, night sweats, weight 
loss), and/or elevated levels of serum lactate 
dehydrogenase and uric acid  
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma  
 
 
Clinical presentation 3 
Indolent 
NHL http://www.adamondemand.com/wp-content/themes/ADAMOnDemand2014/images/courses/screenshots/08035509/08035509_06.jpg  
 
 
Clinical presentation 4 
Peripheral adenopathy in indolent NHL 
 https://quizlet.com/21608719/oncology-lymphomas-flash-cards/  
 
 
Clinical presentation 5 
Aggressive NHL 
https://www.withfriendship.com/images/c/14437/Non-Hodgkin-lymphoma-picture.jpg  
 
 
Clinical presentation 6 
Gingival appearance of patient with NHL 
http://exp-oncology.com.ua/article/3228/primary-extranodal-non-hodgkin-s-lymphoma-presenting-as-painful-gingival-swelling  
 
 
Clinical presentation 7 
Spleen, NHL: uniform multicentric involvement of the 
white pulp by a malignant lymphoma 
http://2.bp.blogspot.com/-r0dcUiAFTB4/UXVoP3AC_KI/AAAAAAAAJuE/9al3qgWHV6g/s640/Spleen,+non-Hodgkin+lymphoma.png  
 
 
Clinical presentation 8 
Cutaneous T-Cell NHL 
http://img.medscapestatic.com/pi/meds/ckb/55/36955tn.jpg  
 
 
Diagnosis 1 
• NHL is diagnosed by a tissue biopsy of an enlarged, 
painless lymph node, without of an infection 
• Patient will need some or all of the following tests 
depending on symptoms and the type of the NHL: 
• Lymph node biopsy  
• Imaging tests (X-rays, computed tomography (CT), 
positron emission tomography (PET), magnetic 
resonance imaging (MRI) 
• Blood tests   
http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/non-hodgkins-lymphoma/diagnosis/index.html  
 
 
Diagnosis 2 
• Bone marrow aspiration and biopsy 
• Liver and kidney function tests 
• Spinal tap (lumbar puncture)  
• Immunophenotyping of cells from a lymph node, 
blood or bone marrow to determine what type of 
non-Hodgkin's lymphoma cells are present. 
• Echocardiogram 
• Pulmonary function test 
http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/non-hodgkins-lymphoma/diagnosis/index.html  
 
 
Diagnosis 3 
Posteroanterior (PA) chest radiograph in a man with 
thoracic NHL shows mediastinal widening due to 
grossly enlarged right paratracheal and left 
paratracheal nodes 
http://emedicine.medscape.com/article/203399-workup#c9  
 
 
Diagnosis 4 
Posteroanterior (PA) chest radiograph in a 16-year-old 
male adolescent with thoracic NHL shows subtle 
enlargement of the lower paratracheal lymph nodes 
http://emedicine.medscape.com/article/203399-workup#c9  
 
 
Diagnosis 5 
A large mass in the right parahilar region extending 
into the right upper and middle zones; smaller mass is 
seen in the periphery of the right lower zone; core-
needle biopsy of the larger lesion revealed NHL 
deposits in the lung http://emedicine.medscape.com/article/203399-workup#c9  
 
 
Diagnosis 6 
Extensive uptake in the mediastinal lymph nodes due 
to NHL 
http://emedicine.medscape.com/article/203399-overview  
 
 
Diagnosis 7 
Two sets of before and after FDG-PET scans of two 
patients with NHL treated with Zevalin or Bexxar   
http://www.cancernetwork.com/articles/snm-image-year-shows-radioimmunotherapy%E2%80%99s-effectiveness-against-non-hodgkin%E2%80%99s-lymphoma  
 
 
Diagnosis 8 
PET/CT images  of a patient with NHL before (left) and 
after (right) chemotherapy, showing complete 
response 
http://www.nature.com/onc/journal/v30/n40/fig_tab/onc2011169f2.html  
 
 
Diagnosis 9 
Coloured composite computed tomography (CT) and 
positron emission tomography (PET) scans of sections 
through a patient with growths in the abdomen and 
chest due to NHL 
http://www.nature.com/onc/journal/v30/n40/fig_tab/onc2011169f2.html  
 
 
Diagnosis 10 
Diffuse large B-
cell NHL 
http://img.medscapestatic.com/pi/meds/ckb/55/13655tn.jpg http://f.tqn.com/y/lymphoma/1/W/A/3/-/-/GettyImages-121823109.jpg  
http://www.humpath.com/IMG/jpg_spleen_gamma-delta_lymphoma_06_cd20.jpg  
 
 
Aggressive NHL Aggressive NHL 
Treatment 1   
• The main types of treatment are chemotherapy 
( intravenously e.g. CVP (cyclophosphamide, 
vincristine, prednisolone) with  monoclonal 
antibody drug rituximab, CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisolone), 
FAD (fludarabine, doxorubicin, dexamethasone), or 
FMD (fludarabine, mitoxantrone and 
dexamethasone), radiotherapy (often used as 
a local treatment), and biological (e.g. rituximab, 
ibritumomab, tositumomab, epratuzumab, 
alemtuzumab) therapy  
http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/treatment/types/  
 
 
Treatment 2   
• Some people may have surgery to remove a tumour 
or the spleen 
• Sometimes high dose chemotherapy with a stem 
cell transplant may be used to try to increase the 
chance of curing NHL 
• Some people need only one type of treatment and 
others need more than one 
http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/treatment/types/  
 
 
Prognosis 
• Survival rates for NHL vary widely, depending on the 
lymphoma type, stage, age of the patient, and other 
variables 
• The overall 5-year relative survival rate for patients 
with non-Hodgkin’s lymphoma is 63% and the 10-
year relative survival rate is 51% 
• Survival rates for patients with NHL have greatly 
improved since the early 1990s, especially for 
patients under age 45 
• Advances in treatment have contributed to this 
improvement 
http://www.nytimes.com/health/guides/disease/non-hodgkins-lymphoma/prognosis.html  
 
 
MULTIPLE MYELOMA 
Definition 
• Multiple myeloma (plasma cell myeloma, 
myelomatosis, Kahler's disease - MM), is a cancer of 
plasma cells, in physiological conditions responsible 
for producing normal antibodies, wherein collections 
of their abnormal forms accumulate in the bone 
marrow and interfere with the normal blood cells 
• In most cases of MM abnormal plasma cells produce 
a paraprotein, which can cause kidney failure  
• Bone lesions in MM can lead to hypercalcemia (high 
blood calcium levels) 
https://en.wikipedia.org/wiki/Multiple_myeloma  
Epidemiology  1 
https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=254171  
Epidemiology  2 
Patients with MM 
http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/image/cases_crude_myeloma_png.png  
Epidemiology  3 
Patients with MM 
http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/image/world_inc_myeloma_png.png  
Risk factors and etiology 1  
• The risk of MM goes up as people age, most cases 
diagnosed at least after 65 years 
• Men are slightly more likely to develop MM than 
women 
• MM is more than twice as common in African 
Americans than in white Americans, the reason is 
not known 
• Exposure to radiation may increase the risk of MM  
http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-risk-factors  
Risk factors and etiology 2  
• Family history 
• Someone who has a sibling or parent with MM is 4 
times more likely to get it than would be expected   
• Being overweight or obese increases a risk of 
developing MM 
• Having other plasma cell diseases 
• People with monoclonal gammopathy of 
undetermined significance (MGUS) or solitary 
plasmacytoma may will develop MM 
http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-risk-factors  
Mechanisms  1 
• B- lymphocytes start in the bone marrow and move 
to the lymph nodes 
• As they progress, they mature and display different 
proteins on their cell surface 
• B lymphocytes  activated to secrete antibodies are 
known as plasma cells 
• MM develops in B lymphocytes after they have left 
the part of the lymph node known as the germinal 
center  
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Mechanisms  2 
• The normal cell line most closely associated with 
MM cells is generally taken to be either an 
activated memory B cell or the precursor to plasma 
cells, the plasmablast 
• The immune system keeps the proliferation of B 
cells and the secretion of antibodies under tight 
control 
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Mechanisms  3 
• When chromosomes and genes are damaged, often 
through rearrangement, this control is lost    
• The result is proliferation of a plasma cell clone and 
genomic instability that leads to further mutations 
and translocations 
• Production of cytokines (especially IL-6) by the 
plasma cells causes much of their localised damage, 
such as osteoporosis, and creates a 
microenvironment in which the malignant cells 
thrive  
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Mechanisms  4 
• Angiogenesis (the attraction of new blood vessels) 
is increased. 
• The produced antibodies are deposited in various 
organs, leading to kidney failure, polyneuropathy 
and various other myeloma-associated symptoms. 
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Mechanisms  5 
 Manifestations of MM 
http://www.jahjournal.org/article.asp?issn=1658-5127;year=2015;volume=6;issue=2;spage=58;epage=63;aulast=Olaniyi  
Mechanisms  6 
 Bone marrow in MM 
http://www.themmrf.org/wp-content/uploads/healthy_bone-marrow-and-multiple-myeloma-bone-marrow.png  
Classification  1 
International Myeloma Working Group diagnostic 
criteria 
• Symptomatic myeloma: M-protein ≥ 30 g/L and/or 
bone marrow clonal cells ≥ 10% and evidence end-
organ damage; manifested by CRAB (calcium, renal 
failure, anemia, and bone lesions: increased serum 
calcium ≥ 11.5 mg/100 mL; renal insufficiency 
[serum creatinine > 1.73 mmol/L]; normochromic, 
normocytic anemia with a hemoglobin value > 2 
g/100 mL below the lower limit of normal or a 
hemoglobin value < 10 g/100 mL; lytic lesions, 
severe osteopenia, or pathologic fractures)  
http://emedicine.medscape.com/article/2007195-overview  
Classification  3 
International Myeloma Working Group diagnostic 
criteria 
• Nonsecretory myeloma: Absence of an M-protein in 
the serum and urine, bone marrow plasmacytosis, 
and ROTI 
http://emedicine.medscape.com/article/2007195-overview  
Classification  4 
International Staging System 
 
• Stage I: Serum beta-2 microglobulin < 3.5 mg/L and 
serum albumin ≥ 3.5 g/dL 
• Stage II: Neither stage I nor stage III 
• Stage III: Serum beta-2 microglobulin ≥ 5.5 mg/L 
http://emedicine.medscape.com/article/2007195-overview  
Clinical presentation 1 
• Bone pain   
• Pathologic fractures   
• Spinal cord compression (back pain, weakness, 
numbness, or dysesthesias in the extremities)   
• Bleeding resulting from thrombocytopenia, and 
monoclonal protein absorption of clotting factors   
• Hypercalcemia (confusion, somnolence, bone pain, 
constipation, nausea, and thirst)   
• Infection through abnormal humoral immunity and 
leukopenia   
 
http://emedicine.medscape.com/article/204369-clinical  
 
 
Clinical presentation 2 
• Hyperviscosity (generalized malaise, infection, fever, 
paresthesia, sluggish mentation, sensory loss, 
headaches, somnolence, hazy vision, etc., when 
serum viscosity is greater than 4 times that of 
normal serum)  
• Neurologic symptoms (carpal tunnel syndrome, 
meningitis (especially that resulting from 
pneumococcal or meningococcal infection), some 
peripheral neuropathies, etc.)  
http://emedicine.medscape.com/article/204369-clinical  
 
 
Clinical presentation 3 
• Kidney problems, that can lead to symptoms like 
weakness, shortness of breath, itching, leg swelling 
• Anemia, which may be quite severe  
• Signs and symptoms of light chain amyloidosis 
(heart problems, enlarged liver and spleen, 
enlarged tongue, bleeding into the skin around the 
eyes (“raccoon eyes”),diarrhea)  
 
http://emedicine.medscape.com/article/204369-clinical  
 
 
Clinical presentation 4 
Herpes 
zoster 
(shingles) 
myelomapennstate.net/Contents/04c-ClinManifest.htm  linicalimagingscience.org/article.asp?issn=2156-7514;year=2013;volume=3;issue=2;spage=6;epage=6;aulast=Vinayachandran  
 
 
Amyloidosis 
infiltrating the 
tongue 
Swelling in 
the mandible 
Clinical presentation 5 
http://www.bloodjournal.org/content/120/1/20?sso-checked=true  
 
 Cell dissemination and 
metastasis in MM: (A) 
Multiple lytic lesions in the 
skull; B) MM cells 
metastasize to areas 
outside the BM; (C) A large 
subcutaneous mass on the 
shoulder (D) Circulating 
tumor plasma cells in the 
peripheral blood 
Diagnosis 1 
Diagnosis should be based on the following tests:  
• Detection and evaluation of the monoclonal (M-) 
component by serum and/or urine protein 
electrophoresis (concentrate of 24 h urine 
collection); nephelometric quantification of IgG, IgA 
and IgM immunoglobulins; characterisation of the 
heavy and light chains by immunofixation; and 
serum-free light-chain (FLC) measurement   
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma  
 
 
Diagnosis 2 
Diagnosis should be based on the following tests:  
• Evaluation of bone marrow (BM) plasma cell 
infiltration: BM aspiration and/or biopsies are the 
standard options to evaluate the number and 
characteristics. Moreover, the BM sample should be 
used for cytogenetic/fluorescence in 
situ hybridization (FISH) studies and also has the 
potential for immunophenotypic and molecular 
investigations    
 
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma  
 
 
Diagnosis  4 
• Fluorodeoxyglucose positron emission tomography   
• Complete blood cell count, with differential   
• Serum creatinine and calcium level 
• Evaluation of lytic bone lesions  
• A magnetic resonance imaging (MRI) or computed 
tomography (CT) scan   
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma  
 
 
Diagnosis  5 
Diagram Distribution of MM 
http://radiopaedia.org/images/1696350  
 
 
Diagnosis  6 
http://radiopaedia.org/images/  
 
 
Diagnosis  7 
http://radiopaedia.org/images/  
 
 
Diagnosis  8 
http://radiopaedia.org/images/  
 
 
Diagnosis  9 
http://radiopaedia.org/images/  
 
 
Diagnosis  10 
http://emedicine.medscape.com/article/204369-overview  
 
 
Bone marrow aspirate demonstrating plasma cells of 
multiple myeloma 
Diagnosis  11 
• Genetic testing 
• Some myeloma centers now employ genetic testing, 
which they call a “gene array”  
• By examining DNA, oncologists can determine if 
patients are high risk or low risk of the cancer 
returning quickly following treatment  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Diagnosis  12 
• Genetic testing 
• Cytogenetic analysis of myeloma cells may be 
of prognostic value, with deletion of chromosome 
13, non-hyperdiploidy and the balanced 
translocations t(4;14) and t(14;16) conferring a 
poorer prognosis. The 11q13 and 6p21 cytogenetic 
abnormalities are associated with a better 
prognosis   
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Diagnosis  13 
• Genetic testing 
• Prognostic markers such as these are always 
generated by retrospective analyses, and it is likely 
that new treatment developments will improve the 
outlook for those with traditionally "poor-risk" 
disease  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Diagnosis  14 
Genetic classifications of MM  
http://www.bloodjournal.org/content/121/6/884?sso-checked=true  
 
 
Treatment  1 
• Focused on therapies that decrease the clonal 
plasma cell population and consequently decrease 
the signs and symptoms of disease 
• If the disease is completely asymptomatic, 
treatment is typically deferred, or restricted to 
clinical trials 
• In addition to direct treatment of the plasma cell 
proliferation, bisphosphonates are routinely 
administered to prevent fractures   
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  2 
• If needed, red blood cell transfusions 
or erythropoietin can be used for management of 
anemia 
• Bortezomib has the first therapeutic proteasome 
inhibitor approved by the U.S. FDA for treating 
relapsed multiple myeloma  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  3 
Initial therapy 
• High-dose chemotherapy (lenalidomide–
dexamethasone, bortezomib based regimens, 
and lenalidomide–dexamethasone) with autologous 
hematopoietic stem-cell transplantation has 
become the preferred treatment for patients under 
the age of 65 
• Allogeneic stem cell transplantation, has the 
potential for a cure, but is used in a very small 
percentage of patients   
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  4 
Initial therapy 
• Patients over age 65 and patients with significant 
concurrent illness often cannot tolerate stem cell 
transplantation, and for them the standard of care 
has been chemotherapy with melphalan and 
prednisone,  with bortezomib 
• Deep venous thrombosis and pulmonary embolism 
are the major side effects of high-dose 
chemotherapy  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  5 
Maintenance therapy 
• Sometimes after the initial treatment an ongoing 
maintenance therapy is offered 
• In younger patients, maintenance therapy 
with thalidomide appears to increase tumor burden 
reduction further, which translates into prolonged 
progression-free survival 
• Maintenance therapy with thalidomide, 
lenalidomide, or bortezomib is still of questionable 
benefit  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  6 
• Relapse 
• The natural history of MM is of relapse following 
treatment 
• For patients with relapsed 
disease, proteasome inhibitor bortezomib is a 
recent addition to the therapeutic arsenal 
(lenalidomide, thalidomide), especially as second 
line therapy  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Treatment  7 
• Palliative care 
• Multiple national cancer treatment guidelines 
recommend early palliative care for people with 
advanced MM at the time of diagnosis as well as for 
anyone who has significant symptoms 
• Palliative care is appropriate at any stage of MM 
and can be provided alongside curative treatment 
• In addition to addressing symptoms of cancer, 
palliative care helps manage unwanted side-effects, 
such as pain and nausea related to treatments 
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Prognosis 
• With high-dose therapy followed by autologous 
stem cell transplantation, the median survival has 
been estimated  to be approximately 5 years 
• The International Staging System can help to predict 
survival  
• The prognoses for patients with MM, as those with 
other diseases, are not the same for everyone: 
older patients often are experiencing other serious 
diseases, which affect survival and younger patients 
might have much longer survival rates 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Prophylaxis 
• Prophylaxis is treatment that aims to stop a 
lymphoma elsewhere in the body  
• It can be difficult to treat once it develops, so 
sometimes needs a preventive treatment 
• This treatment may be given as well as the usual 
chemotherapy for the lymphoma or may already be 
part of a particular regimen  
https://www.google.com.ua/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=secondary+prophylaxis+of+lymphoma 
Abbreviations  
• CT         - computed tomography 
• EBV       - Epstein-Barr virus  
• FDA      - U.S. Food and Drug Administration  
• FISH     -fluorescence in situ hybridization   
• HCV      - hepatitis C virus  
• HHV8   - human herpes virus 8  
• HIV       - human immunodeficiency virus 
• HL         - Hodgkin lymphoma 
• HTLV-1 - human T-cell leukemia/lymphoma virus  
• IWF       - National Cancer Institute’s Working Formulation 
• MRI       - magnetic resonance imaging 
• NHL      - non-Hodgkin lymphoma 
• PET       - positron emission tomography 
• REAL     - Revised European-American Classification of Lymphoid Neoplasms  
• RSC       - Reed-Sternberg cells  
• WHO    - World Health Organization 
• MGUS  - monoclonal gammopathy of undetermined significance   
• MM      - multiple myeloma   
Diagnostic guidelines 
 Best practice in lymphoma diagnosis and reporting 
• Control of pain in adults with cancer: a national clinical guideline   
• Referral guidelines for suspected cancer   
• Consensus recommendations for the management of cutaneous B-
cell lymphomas   
• Diagnosis and treatment of primary CNS lymphoma in 
immunocompetent patients: guidelines from the European 
Association for Neuro-Oncology 
• Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up 
•  NCCN clinical practice guidelines in oncology: non-Hodgkin's 
lymphoma   
 
